Compile Data Set for Download or QSAR
Report error Found 90 Enz. Inhib. hit(s) with all data for entry = 8327
TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241685(US9718820, Compound 89 | US9409915, 89)
Affinity DataIC50: 0.530nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241633(US9718820, Compound 16 | US9409915, 16)
Affinity DataIC50: 0.590nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241638(US9718820, Compound 21 | US9409915, 21)
Affinity DataIC50: 0.690nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241686(US9718820, Compound 90 | US9409915, 90)
Affinity DataIC50: 0.730nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241636(US9718820, Compound 19 | US9409915, 19)
Affinity DataIC50: 0.840nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241637(US9718820, Compound 20 | US9409915, 20)
Affinity DataIC50: 0.950nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241620(US9718820, Compound 59A | US9409915, 59)
Affinity DataIC50: 1.10nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241689(US9718820, Compound 93 | US9409915, 93)
Affinity DataIC50: 1.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241631(US9718820, Compound 14 | US9409915, 14)
Affinity DataIC50: 1.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241639(US9409915, 22)
Affinity DataIC50: 1.40nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241606(US9718820, Compound 57 | US9409915, 57)
Affinity DataIC50: 1.60nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241634(US9718820, Compound 17 | US9409915, 17)
Affinity DataIC50: 1.70nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241680(US9718820, Compound 83 | US9409915, 83)
Affinity DataIC50: 1.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241632(US9718820, Compound 15 | US9409915, 15)
Affinity DataIC50: 1.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241681(US9718820, Compound 84 | US9409915, 84)
Affinity DataIC50: 1.90nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241666(US9718820, Compound 58 | US9409915, 58)
Affinity DataIC50: 2nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241688(US9718820, Compound 92 | US9409915, 92)
Affinity DataIC50: 2.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241667(US9718820, Compound 63A | US9409915, 63)
Affinity DataIC50: 3.10nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241669(US9409915, 65)
Affinity DataIC50: 3.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241619(US9718820, Compound 11 | US9409915, 11)
Affinity DataIC50: 3.5nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241687(US9718820, Compound 91 | US9409915, 91)
Affinity DataIC50: 3.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241663(US9718820, Compound 54 | US9409915, 54)
Affinity DataIC50: 4.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241691(US9718820, Compound 97 | US9409915, 97)
Affinity DataIC50: 4.90nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241622(US9409915, 61)
Affinity DataIC50: 5.30nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241609(US9718820, Compound 103 | US9409915, 103)
Affinity DataIC50: 5.40nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241601(US9409915, 9)
Affinity DataIC50: 5.60nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241675(US9718820, Compound 76 | US9409915, 76)
Affinity DataIC50: 5.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241600(US9409915, 8)
Affinity DataIC50: 6nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241659(US9718820, Compound 49 | US9409915, 49)
Affinity DataIC50: 6.40nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241670(US9718820, Compound 66 | US9409915, 66)
Affinity DataIC50: 6.5nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241640(US9718820, Compound 24 | US9409915, 24)
Affinity DataIC50: 7.40nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241646(US9409915, 32)
Affinity DataIC50: 7.60nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241635(US9409915, 18)
Affinity DataIC50: 8.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241612(US9718820, Compound 71 | US9409915, 71)
Affinity DataIC50: 8.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241618(US9718820, Compound 28 | US9409915, 28)
Affinity DataIC50: 11nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241629(US9718820, Compound 12 | US9409915, 12)
Affinity DataIC50: 11nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241641(US9409915, 25)
Affinity DataIC50: 12nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241624(US9409915, 2)
Affinity DataIC50: 13nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241668(US9718820, Compound 64 | US9409915, 64)
Affinity DataIC50: 14nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241692(US9718820, Compound 98 | US9409915, 98)
Affinity DataIC50: 14nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241677(US9718820, Compound 78 | US9409915, 78)
Affinity DataIC50: 16nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241628(US9718820, Compound 10 | US9409915, 10)
Affinity DataIC50: 16nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241597(US9718820, Compound 5 | US9409915, 5)
Affinity DataIC50: 16nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241598(US9718820, Compound 3 | US9409915, 3)
Affinity DataIC50: 17nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241616(US9718820, Compound 31 | US9409915, 31)
Affinity DataIC50: 18nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241703(US9409915, 112)
Affinity DataIC50: 19nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241656(US9409915, 46)
Affinity DataIC50: 19nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241676(US9718820, Compound 77 | US9409915, 77)
Affinity DataIC50: 20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241610(US9718820, Compound 80 | US9409915, 79)
Affinity DataIC50: 20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

TargetTransient receptor potential M8 protein(Dog)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM241654(US9409915, 43)
Affinity DataIC50: 22nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2017
Entry Details
Go to US Patent

Displayed 1 to 50 (of 90 total ) | Next | Last >>
Jump to: